Novo Nordisk Reveals Major Efficacy Milestone for CagriSema in REIMAGINE 2 Diabetes Trial

Novo Nordisk announced breakthrough clinical results demonstrating that CagriSema, an innovative fixed-dose combination therapy, significantly outperformed its individual components in managing both blood glucose levels and body weight among adults with type 2 diabetes. The Danish pharmaceutical company’s findings from the REIMAGINE 2 trial represent a critical step forward in addressing the dual challenge of glucose control and weight reduction in diabetic populations.

Superior Blood Sugar and Weight Control Demonstrated

The REIMAGINE 2 efficacy and safety study, which tracked patients through 68 weeks of treatment, revealed that CagriSema achieved an HbA1c reduction of 1.91 percentage points alongside a notable 14.2% weight loss across all tested dose levels. These results marked a clear advantage when compared directly to semaglutide monotherapy. By combining cagrilintide (a long-acting amylin receptor agonist) with semaglutide (a long-acting GLP-1 receptor agonist), researchers demonstrated that the dual-mechanism approach generates superior outcomes beyond what either therapy delivers independently.

Throughout the trial, CagriSema maintained a safety and tolerability profile consistent with established incretin and amylin-based therapies, with no unexpected safety signals emerging.

Combination Strategy Shows Promise Over Single-Agent Therapy

The success of this combination approach reflects a growing recognition in diabetes care that addressing multiple biological pathways simultaneously may yield better clinical outcomes. CagriSema’s superior efficacy versus its individual components underscores the therapeutic potential of this integrated strategy. Martin Holst Lange, Novo Nordisk’s executive vice president and chief scientific officer, highlighted the significance: “By combining semaglutide and cagrilintide, we’re seeing superior outcomes in both blood glucose control and weight reduction that exceed what either therapy achieves alone. These results strengthen our confidence that CagriSema could establish a new treatment paradigm as the first amylin-based combination therapy for individuals with type 2 diabetes who prioritize weight loss.”

Regulatory Path Forward and Market Reception

Building on successful outcomes from the REIMAGINE 1 trial and REDEFINE 3 program, Novo Nordisk plans to engage with regulatory authorities to establish the approval pathway for CagriSema in type 2 diabetes treatment. The company had previously submitted the compound to the US FDA in December 2025 based on REDEFINE 1 and REDEFINE 2 data for weight management indication. Detailed results from REIMAGINE 2 are scheduled for presentation at a major scientific conference during 2026.

On the NYSE, Novo Nordisk shares closed slightly lower at $58.93, declining 0.8% during Monday’s regular session. However, the overnight trading session reflected renewed interest, with shares climbing approximately 0.4% to $59.19, suggesting positive market reassessment of the trial outcomes and the compound’s commercial potential.